Hepion Pharmaceuticals: Gravitas acquires 19.9% stake

Gravitas Collective's reported stake equals 19.9% of Hepion's common stock, and it said it may acquire more shares from time to time.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. (HEPA) common stock was acquired by Gravitas Collective Corp., which received 25,000,000 shares on October 6, 2026, in exchange for the membership interests of Gravitas Life Sciences, Inc., which Gravitas Collective solely owned. Gravitas Collective reported beneficial ownership of 25,000,000 shares, equal to 19.9% of the class, with sole voting and dispositive power. The percentage was based on 125,073,217 Hepion common shares outstanding as of October 6, 2026. Gravitas Collective said it acquired the shares for investment purposes and may make further acquisitions from time to time; it reported no other plans or proposals relating to the other matters covered by its disclosure.

Key Figures

Beneficially owned shares: 25,000,000 shares Class ownership: 19.9% Common shares outstanding: 125,073,217 shares

3 metrics

Beneficially owned shares 25,000,000 shares Reported by Gravitas Collective

Class ownership 19.9% Gravitas Collective's reported beneficial ownership

Common shares outstanding 125,073,217 shares As of October 6, 2026

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, membership interests

4 terms

beneficially owned regulatory

"25,000,000 shares beneficially owned by the reporting person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power regulatory

"Sole Voting Power 25,000,000.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power regulatory

"Sole Dispositive Power 25,000,000.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

membership interests financial

"in exchange for the membership interests of Gravitas Life Sciences, Inc."

An ownership stake in a limited liability company (LLC) that represents a holder’s share of the business’s profits, losses, and decision-making power. Think of it like a slice of the company’s pie and a seat at its management table: it determines how much money the owner can receive and how much influence they have over company choices. Investors care because these interests affect returns, control, transferability, and tax treatment.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HEPA shares does Gravitas Collective own?

Gravitas Collective reported beneficial ownership of 25,000,000 Hepion common shares, representing 19.9% of the class.

How did Gravitas Collective acquire HEPA shares?

On October 6, 2026, Gravitas Collective received 25,000,000 Hepion common shares in exchange for its membership interests in Gravitas Life Sciences, Inc., which it solely owned.

Does Gravitas Collective plan to acquire more HEPA shares?

Gravitas Collective said it may make further acquisitions of Hepion common stock from time to time. It also reported no other plans or proposals relating to the other matters covered by its disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/26/2026 - 08:00 PM EDT Accepted by SEC EDGAR 10/26/2026 - 08:00 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Hepion Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

426897401

(CUSIP Number)

Chase LoPriore
Gravitas Collective Corp., 155 Pompton Ave., Suite 204
Verona, NJ, 07044
(732) 902-4000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/06/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 426897401

1

Name of reporting person

Gravitas Collective Corp.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 25,000,000.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 25,000,000.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

25,000,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

19.9 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

(1) The percentage reported in row 13 above is calculated with a numerator of 25,000,000 shares beneficially owned by the reporting person a denominator of 125,073,217 shares of Common Stock outstanding as of October 6, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Hepion Pharmaceuticals, Inc.
(c)	Address of Issuer's Principal Executive Offices: c/o Hepion Pharmaceuticals, Inc.,, 22 West Street, Verona, NEW JERSEY , 07701.
Item 2.	Identity and Background
(a)	This Statement is being filed on behalf of Gravitas Collective Corp. (the "Reporting Person").
(b)	The business address of the Reporting Person is 155 Pompton Ave., Suite 204, Verona, NJ 07044.
(c)	Not applicable.
(d)	No
(e)	No
(f)	The Reporting Person is a New Jersey corporation.
Item 3.	Source and Amount of Funds or Other Consideration
	On October 6, 2026, the Reporting Person received 25,000,000 shares Common Stock of the Issuer in exchange for the membership interests of Gravitas Life Sciences, Inc. solely owned by the Reporting Person.
Item 4.	Purpose of Transaction
	The Common Stock owned by the Reporting Person was acquired for investment purposes. The Reporting Person may make further acquisitions of the Common Stock from time to time. Except for the foregoing, the Reporting Person has no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	See response to Item 5(a) on the cover page for the Reporting Person.
(b)	See responses to Item 5(b) on the cover page for the Reporting Person.
(c)	Not applicable.
(d)	Not applicable.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Other than as described herein, the Reporting Person does not have any contracts, arrangements, understandings or relationships with respect to the securities of the Issuer.
Item 7.	Material to be Filed as Exhibits.
	None

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Gravitas Collective Corp.

Signature:	/s/ Chase LoPriore
Name/Title:	Chase LoPriore, CEO
Date:	10/26/2026